Domestic pharma market to touch $130 bn by 2030 

Cumulative FDI in pharma sector crossed $20 billion in September 2022

Published - January 31, 2023 07:38 pm IST - HYDERABAD

India’s domestic pharmaceutical market, estimated to be $41 billion in 2021, is likely to touch $130 billion by 2030, Economic Survey 2022-23, tabled in Parliament on Tuesday, showed.

Highlighting the role of Indian pharmaceuticals industry globally, the Survey showed the country was ranked third worldwide in terms of production of pharma products by volume and 14th by value. It was the largest provider of generic medicines globally, having a 20% share in global supply by volume, besides being a vaccine manufacturer with a market share of 60% globally.

Pharma exports from the country have been robust, sustaining positive growth despite the global trade disruptions and drop in demand for COVID-19-related treatments, according to the Survey. The exports clocked a healthy 24% growth in FY21, on the back of COVID-19-induced demand for critical drugs and other supplies made to over 150 countries. In FY22, pharma export were robust, sustaining growth despite global trade disruptions and drop in demand for COVID-19-related treatments.

Growth momentum

Carrying forward this growth momentum, drug and pharmaceutical exports during April-October 2022 were 22% higher compared with the corresponding pre-pandemic period in FY20, according to the Survey.

Cumulative FDI in the pharma sector crossed the $20 billion-mark by September 2022. Further, FDI inflows had increased fourfold over five years until September 2022, to $699 million, supported by investor-friendly policies and a positive outlook for the industry.

On its part, the government has undertaken several measures to improve the infrastructural facilities for the pharma sector. Strengthening the Pharmaceutical Industry (SPI) scheme was launched in March 2022 with ₹500 crore outlay for the period FY 21-22 to FY 25-26. The objectives of the programme are to strengthen the infrastructure facilities by providing financial assistance to pharma clusters to create common facilities; upgrade production facilities of MSMEs to meet national and international regulatory standards by providing interest subvention or capital subsidy on their capital loans; and promoting knowledge and awareness of the pharmaceutical and medical devices industry.

Three PLI schemes

The Survey also referred to the three production-linked incentive (PLI) schemes unveiled by the government focussed on pharmaceuticals; critical key starting materials/drug intermediaries/active pharmaceutical ingredients; and medical devices. The PLI schemes, for various industries, seek to unlock manufacturing capacity, boost exports, reduce import dependence and lead to job creation for both skilled and unskilled labour.

Striking a cautious note, the survey chapter on industries said “on the downside, exports are slowing down and are likely to moderate along with the probable global economic slowdown.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.